Skip to content

Michael Freissmuth

5 papers in the library · 320 citations · publishing 2011-2021

Papers

Sort Most recent Most cited

Tropane-Based Ibogaine Analog Rescues Folding-Deficient Serotonin and Dopamine Transporters.

ACS Pharmacology & Translational Science April 9, 2021 Shreyas Bhat, Daryl A. Guthrie, Ameya Kasture et al. 37 citations

Missense mutations that give rise to protein misfolding are rare, but collectively, defective protein folding diseases are consequential. Folding deficiencies are amenable to pharmacological correction (pharmacochaperoning), but the underlying mechanisms remain enigmatic. Ibogaine and its active metabolite noribogaine correct folding defects in the dopamine transporter (DAT), but they rescue...

A tropane-based ibogaine analog rescues folding-deficient SERT and DAT

bioRxiv (Cold Spring Harbor Laboratory) July 14, 2020 Shreyas Bhat, Daryl A. Guthrie, Ameya Kasture et al. 3 citations preprint

Abstract Missense mutations that give rise to protein misfolding are rare, but collectively, defective protein folding diseases are consequential. Folding deficiencies are amenable to pharmacological correction (pharmacochaperoning), but the underlying mechanisms remain enigmatic. Ibogaine and its active metabolite noribogaine correct folding defects in the dopamine transporter (DAT), but they...

SLC6 Transporter Folding Diseases and Pharmacochaperoning.

Handbook of experimental pharmacology 2018 Michael Freissmuth, Thomas Stockner, Sonja Sucic 44 citations

The human genome encodes 19 genes of the solute carrier 6 (SLC6) family; non-synonymous changes in the coding sequence give rise to mutated transporters, which are misfolded and thus cause diseases in the affected individuals. Prominent examples include mutations in the transporters for dopamine (DAT, SLC6A3), for creatine (CT1, SLC6A8), and for glycine (GlyT2, SLC6A5), which result in...

The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters.

The Journal of biological chemistry May 25, 2012 Simon Bulling, Klaus Schicker, Yuan-Wei Zhang et al. 124 citations

Ibogaine, a hallucinogenic alkaloid proposed as a treatment for opiate withdrawal, has been shown to inhibit serotonin transporter (SERT) noncompetitively, in contrast to all other known inhibitors, which are competitive with substrate. Ibogaine binding to SERT increases accessibility in the permeation pathway connecting the substrate-binding site with the cytoplasm. Because of the structural...

The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’), methamphetamine and d-amphetamine

Biological Chemistry January 2, 2011 Thomas Steinkellner, Michael Freissmuth, Harald H. Sitte et al. 112 citations

Abstract Amphetamine (‘Speed’), methamphetamine (‘Ice’) and its congener 3,4-methylenedioxymethamphetamine (MDMA; ‘Ecstasy’) are illicit drugs abused worldwide for their euphoric and stimulant effects. Despite compelling evidence for chronic MDMA neurotoxicity in animal models, the physiological consequences of such toxicity in humans remain unclear. In addition, distinct differences in the...